^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ESG206

    i
    Other names: ESG206
    Associations

    News

    Trials
    Company:
    Escugen Biotechnology
    Drug class:
    BAFF-R inhibitor
    Related drugs:
    Associations

    News

    Trials
    25d
    A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Shanghai Escugen Biotechnology Co., Ltd
    New P2 trial
    |
    ESG206
    5ms
    A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=0, Withdrawn, Shanghai Escugen Biotechnology Co., Ltd | N=12 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • First-in-human
    |
    ESG206
    5ms
    A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=13, Completed, Shanghai Escugen Biotechnology Co., Ltd | N=10 --> 13 | Trial completion date: Dec 2025 --> Jan 2025 | Trial primary completion date: Aug 2025 --> Jan 2025 | Recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    ESG206
    9ms
    A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P1/2, N=84, Recruiting, Shanghai Escugen Biotechnology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ESG206
    10ms
    A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=10, Recruiting, Shanghai Escugen Biotechnology Co., Ltd | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    ESG206
    12ms
    A Phase 1/2 Study of ESG206 in Patients with Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P1/2, N=84, Not yet recruiting, Shanghai Escugen Biotechnology Co., Ltd
    New P1/2 trial
    |
    ESG206
    over1year
    A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Shanghai Escugen Biotechnology Co., Ltd | Trial completion date: May 2025 --> Dec 2026 | Trial primary completion date: Jan 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    ESG206
    over2years
    A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=10, Recruiting, Shanghai Escugen Biotechnology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ESG206